A Randomized Phase II Study of Nuclear Factor-kappa B (NF-kB) Inhibition During Induction Chemotherapy for Patients with Acute Myelogenous Leukemia (AML)

Print this page

A Randomized Phase II Study of Nuclear Factor-kappa B (NF-kB) Inhibition During Induction Chemotherapy for Patients with Acute Myelogenous Leukemia (AML)

This trial will determine if salicylate-mediated NF-kB suppression results in suppression of NF-kB target gene expression and/or chemotherapy drug efflux in AML cells. If inhibition of these biologically relevant endpoints can be demonstrated in > 50% of patients, we will propose a phase III multi-institutional study to determine the effects of salicylate on complete remission rates.

Protocol Number020803
Principal InvestigatorRoger Strair
PhasePhase II
ScopeLocal
Applicable Disease SitesMyeloid and Monocytic Leukemia
Therapies InvolvedChemotherapy multiple agents systemic
Drugs InvolvedCYTARABINE
Idarubicin (Zavedos)
Choline Magnesium Trisalicylate(Trilisate)
Participating InstitutionsRutgers Cancer Institute of New Jersey

For further information on this clinical trial, please contact us at 732-235-8675 or cinjclinicaltrials@umdnj.edu.